We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Saliva Test Could Improve Diabetes Control and Treatment

By LabMedica International staff writers
Posted on 31 Jul 2018
Print article
Image: The Dionex Ultimate 3000 UHPLC system coupled with the high-resolution nano-ESI Orbitrap-Elite mass spectrometer (Photo courtesy of Thermo Fisher Scientific).
Image: The Dionex Ultimate 3000 UHPLC system coupled with the high-resolution nano-ESI Orbitrap-Elite mass spectrometer (Photo courtesy of Thermo Fisher Scientific).
People with type 1 diabetes do not produce enough insulin. The hormone insulin is required for the body to use sugar for energy, so lack of insulin causes unused sugar to accumulate in the blood. This excess sugar in turn leads to complications like cardiovascular, kidney, eye and nerve damage.

With no known cure for type 1 diabetes, the key to preventing these complications is careful control of blood sugar levels. This is achieved with insulin injections, balanced with lifestyle factors like diet and exercise, and requires regular blood testing to monitor sugar control. However, this invasive monitoring can be problematic, particularly in children and adolescents.

Scientists at the National and Kapodistrian University of Athens (Athens, Greece) and their colleagues enrolled a total of 36 subjects who were allocated in three groups. Group 1 (G1) consisted of 12 type 1 diabetic patients with poor glycemic control, group 2 (G2) of 12 patients with satisfactory glycemic control while the control group (Ctrl) comprised of 12 healthy subjects sex-and-aged-matched accordingly. HbA1c values ≥7.5% (58 mmol/mol) indicated poor glycemic control for type 1 diabetes.

The team collected unstimulated whole saliva from all participants. For each sample a total protein amount of 50 μg was measured with the Bradford assay. Labeled peptide samples were stored at −20 °C until they were analyzed by high-pH Reversed Phase (RP) Chromatography. High-pH RP C18 fractionation of the iTRAQ-8plex labeled peptides was performed on the Dionex P680 pump equipped with PDA-100 photodiode array detector using the Waters, XBridge C18 column. All Liquid chromatography–mass spectrometry (LC-MS) analysis were performed on the Dionex Ultimate 3000 UHPLC system coupled with the high resolution nano-ESI Orbitrap-Elite mass spectrometer.

The scientists used a highly sensitive technique and identified and quantified more than 2,000 different proteins. They found that young type 1 diabetics with good blood sugar control had similar saliva protein profiles to non-diabetics. In contrast, young people with poorly controlled type 1 diabetes showed a very different saliva protein profile. The differences were in proteins known to have key roles in inflammation, clotting and blood vessel function, processes that are disrupted by high blood sugar and thereby underlie the major long-term complications of diabetes.

The authors concluded that in-depth analysis of data from this population indicated that differentially expressed proteins are related to acute phase response, endothelial dysfunction, inflammatory and coagulation processes in type I diabetes mellitus. The study was originally published on April 18, 2018, in the journal Frontiers in Physiology.

Related Links:
University of Athens

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
AST Cards
Antimicrobial Susceptibility Testing Cards

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.